Prenatal Intravenous Magnesium at 30-34 Weeks' Gestation and Neurodevelopmental Outcomes in Offspring: The MAGENTA Randomized Clinical Trial.

ABSTRACT:

Importance

Intravenous magnesium sulfate administered to pregnant individuals before birth at less than 30 weeks' gestation reduces the risk of death and cerebral palsy in their children. The effects at later gestational ages are unclear.

Objective

To determine whether administration of magnesium sulfate at 30 to 34 weeks' gestation reduces death or cerebral palsy at 2 years.

Design, setting, and participants

This randomized clinical trial enrolled pregnant individuals expected to deliver at 30 to 34 weeks' gestation and was conducted at 24 Australian and New Zealand hospitals between January 2012 and April 2018.

Intervention

Intravenous magnesium sulfate (4 g) was compared with placebo.

Main outcomes and measures

The primary outcome was death (stillbirt

SUBMITTER: Crowther CA 

PROVIDER: S-EPMC10427942 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature